Iconovo

Iconovo EBIT per Employee

The EBIT per Employee of Iconovo (ICO.ST) as of Oct 30, 2026 is -1.37 M SEK. In the previous year, EBIT per Employee was -1.27 M SEK — a change of 7.79% (lower).

EBIT per Employee

-1.37 MSEK

YoY

7.79%

Last updated:

EBIT per Employee of Iconovo is 2025 -1.37 M SEK. EBIT per Employee of Iconovo was 2024 -1.27 M SEK. It decreases by 7.79% lower compared to the previous year.

The Iconovo EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-181,837.91 SEK
Jan 1, 2019
-367,942.56 SEK
Jan 1, 2020
-515,342.06 SEK
Jan 1, 2021
-828,054.69 SEK
Jan 1, 2022
-1.51 M SEK
Jan 1, 2023
-1.42 M SEK
Jan 1, 2024
-1.27 M SEK
Jan 1, 2025
-1.37 M SEK
The Iconovo EBIT per Employee history
YEAREBIT per EmployeeYoY
-1.37 MSEK+7.79%
-1.27 MSEK-10.55%
-1.42 MSEK-6.17%
-1.51 MSEK+82.50%
-828,054.69SEK+60.68%
-515,342.06SEK+40.06%
-367,942.56SEK+102.35%
-181,837.91SEK-312.29%
85,656.25SEK-23.99%
112,687.50SEK-440.46%
-33,098.75SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Iconovo Stock analysis

What does Iconovo do? Iconovo AB generates revenue through the development, manufacturing, and supply of inhalation products. The company offers device platforms including ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices, and ICOpre, which are part of its device family. Iconovo also provides development programs for generic inhalation products based on therapeutic equivalence, as well as development for inhalation products using generic API and new chemical entity (NCE) applications. These services are targeted at pharmaceutical companies seeking to develop inhalation therapies, particularly for generic and innovative drug delivery systems. The company’s solutions include formulation, analytical testing, and documentation services tied to its device platforms. Iconovo AB’s product portfolio supports the development of pre-metered devices like ICOpre and capsule-based devices such as ICOcap, which are used in respiratory treatment applications. Its clinical trial programs, such as phase I-II trials using ICOone, cater to pharmaceutical clients requiring early-stage development support for inhalation products. Iconovo AB’s business model focuses on providing end-to-end solutions for inhalation product development, from formulation to clinical trials. The company serves pharmaceutical manufacturers who need to bring inhalation therapies to market, leveraging its device platforms and development expertise. Its offerings are structured around specific device types and development pathways, ensuring tailored support for both generic and novel inhalation product launches. Iconovo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Iconovo stock

EBIT per Employee of Iconovo is -1.37 M SEK in 2025.

EBIT per Employee of Iconovo changed from -1.27 M SEK to -1.37 M SEK, representing a 7.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Iconovo since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Iconovo historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Iconovo

All Key Metrics — Iconovo